EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY 4.0

A Randomized, Placebo‐Controlled Trial of Hydroxychloroquine in Incomplete Lupus

Nancy J Olsen iD, Duanping Liao, Judith A James iD, Joel M Guthridge, Cristina Arriens iD, Diane Kamen, Mariko Ishimori, Daniel J Wallace, Christopher Striebich, Sonali Narain, Benjamin F Chong iD, Fan He und 3 weitere

Arthritis & Rheumatology · 2026-04 · 78 (4) · 870-879

DOI: 10.1002/art.43391 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Arthritis & Rheumatology, online erschienen am 12.12.2025. Verfasst von Nancy J Olsen und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania. Hauptthemen laut MEDLINE: Hydroxychloroquine, Lupus Erythematosus, Systemic, Antirheumatic Agents. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, NIAMS NIH HHS, NCATS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Patients with features of systemic lupus erythematosus (SLE) who do not fulfill classification criteria can be designated as incomplete lupus erythematosus (ILE). This condition includes individuals with a high risk of progression to SLE. Treatment of ILE may reduce symptoms, severity, and incidence of SLE.

Methods

Hydroxychloroquine (HCQ) was chosen as an ILE intervention for a randomized, double‐blind trial to determine whether the rate of accumulation of SLE features defined by the 2012 Systemic Lupus Erythematosus International Collaborating Clinics (SLICC) criteria could be reduced. ILE was defined as antinuclear antibody positivity with one to two additional criteria. Patients 15 to 49 years old were eligible. Randomization was 1:1 HCQ to placebo. Evaluations were at 3‐month intervals over 24 months. Meeting SLICC classification sooner required exit.

Results

Participants (N = 187) were randomized at seven sites. After excluding 7 patients who met SLE classification at baseline when screening laboratory data were completed, 180 patients were analyzed: 92 receiving HCQ and 88 receiving placebo. Considering all these enrollees, 55 developed additional criteria. Of the 118 participants who exited early with SLE or who completed 24 months of evaluation, SLE classification developed in 24 (13.3%); another 24 developed additional criteria but did not meet classification. The rates of acquisition of SLICC criteria and progression to SLE were similar in the two groups ( P = 0.72 and P = 0.98, respectively). Development of SLE was associated with new malar rash, oral ulcers, joint tenderness, or pleurisy ( P < 0.04).

Conclusion

Although the Study of Antimalarials in Incomplete Lupus Erythematosus (SMILE) did not show effects of HCQ on ILE progression, the results offer insights into SLE risk in the ILE population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HydroxychloroquineLupus Erythematosus, SystemicAntirheumatic AgentsHumansAdultFemaleDouble-Blind MethodMaleMiddle AgedYoung AdultAdolescentDisease ProgressionAntibodies, AntinuclearTreatment OutcomeSeverity of Illness Index

Substanzen

HydroxychloroquineAntirheumatic AgentsAntibodies, Antinuclear

Autor:innen und Institutionen

  • Department of Medicine, Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania.
  • Department of Public Health Sciences, Penn State College of Medicine, Hershey, Pennsylvania.
  • Department of Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City.
  • Department of Medicine, Medical University of South Carolina, Charleston.
  • Kao Autoimmunity Institute, Cedars Sinai Medical Center, Los Angeles, California.
  • Department of Medicine, Anschutz Medical Center, University of Colorado, Aurora.

ORCID-Profile: Nancy J Olsen, Judith A James, Cristina Arriens, Benjamin F Chong, David R Karp

Förderung

  • NIH HHS
  • NIAMS NIH HHS
  • NCATS NIH HHS
  • National Institutes of Health

Zitieren

APA

Olsen, N. J., Liao, D., James, J. A., Guthridge, J. M., Arriens, C., Kamen, D., Ishimori, M., Wallace, D. J., Striebich, C., Narain, S., Chong, B. F., He, F., Schaefer, E. W., Chinchilli, V. M., & Karp, D. R. (2026). A Randomized, Placebo‐Controlled Trial of Hydroxychloroquine in Incomplete Lupus. Arthritis & Rheumatology, 78(4), 870-879. https://doi.org/10.1002/art.43391

Vancouver

Olsen NJ, Liao D, James JA, Guthridge JM, Arriens C, Kamen D, et al. A Randomized, Placebo‐Controlled Trial of Hydroxychloroquine in Incomplete Lupus. Arthritis & Rheumatology. 2026;78(4):870-879. doi:10.1002/art.43391

BibTeX
@article{Olsen2026,
  author = {Olsen, Nancy J and Liao, Duanping and James, Judith A and Guthridge, Joel M and Arriens, Cristina and Kamen, Diane and Ishimori, Mariko and Wallace, Daniel J and Striebich, Christopher and Narain, Sonali and Chong, Benjamin F and He, Fan and Schaefer, Eric W and Chinchilli, Vernon M and Karp, David R},
  title = {A Randomized, Placebo‐Controlled Trial of Hydroxychloroquine in Incomplete Lupus},
  journal = {Arthritis & Rheumatology},
  year = {2026},
  volume = {78},
  number = {4},
  pages = {870--879},
  doi = {10.1002/art.43391}
}
Kostenlos starten →